Anupam Rama
Stock Analyst at JP Morgan
(3.40)
# 995
Out of 4,734 analysts
247
Total ratings
41.12%
Success rate
5.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANAB AnaptysBio | Maintains: Overweight | $66 → $36 | $15.85 | +127.13% | 10 | Dec 19, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $105 → $102 | $40.00 | +155.00% | 2 | Nov 21, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $33 → $38 | $13.08 | +190.52% | 8 | Nov 21, 2024 | |
| COGT Cogent Biosciences | Maintains: Overweight | $19 → $21 | $8.03 | +161.52% | 4 | Nov 14, 2024 | |
| SLDB Solid Biosciences | Maintains: Overweight | $15 → $12 | $3.27 | +266.97% | 6 | Nov 12, 2024 | |
| FOLD Amicus Therapeutics | Maintains: Overweight | $16 → $17 | $9.41 | +80.66% | 13 | Nov 12, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Underweight | n/a | $1.20 | - | 7 | Nov 11, 2024 | |
| VERA Vera Therapeutics | Maintains: Overweight | $72 → $75 | $33.37 | +124.75% | 8 | Nov 5, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Overweight | $39 → $40 | $18.54 | +115.75% | 3 | Nov 5, 2024 | |
| ZLAB Zai Lab | Maintains: Overweight | $38 → $44 | $26.05 | +68.91% | 11 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $125 | $75.84 | +64.82% | 6 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.66 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $10.14 | +67.65% | 7 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $23 | $18.37 | +25.20% | 3 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $64 → $57 | $29.94 | +90.41% | 15 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $64 → $68 | $34.63 | +96.36% | 5 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $31 | $5.66 | +447.70% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $69 → $66 | $22.18 | +197.57% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $43 | $33.79 | +27.26% | 8 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $173 → $181 | $143.26 | +26.34% | 16 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $10 | $7.08 | +41.24% | 7 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $38 → $36 | $12.54 | +187.08% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.88 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $177 → $175 | $118.00 | +48.31% | 11 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $0.84 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $4.20 | +209.52% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $18 | $9.58 | +87.89% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $9.28 | - | 2 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $9 | $0.95 | +849.37% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $7.17 | - | 6 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.71 | - | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $6.57 | +3,705.18% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.60 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $45.74 | +26.80% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $8.58 | +39.86% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $10.11 | +265.97% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $36.82 | +49.38% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $1.85 | +1,413.51% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $32.42 | +66.56% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.49 | +9,027.79% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $14.13 | +91.08% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $8.00 | +400.00% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $246.27 | -44.37% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $39 | $6.16 | +533.12% | 1 | Dec 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $7.15 | +571.33% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $12.45 | - | 2 | May 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $18 | $0.93 | +1,835.69% | 2 | Mar 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $2.54 | +1,081.10% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $43.84 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.66 | - | 2 | Jul 21, 2017 |
AnaptysBio
Dec 19, 2024
Maintains: Overweight
Price Target: $66 → $36
Current: $15.85
Upside: +127.13%
Ultragenyx Pharmaceutical
Nov 21, 2024
Maintains: Overweight
Price Target: $105 → $102
Current: $40.00
Upside: +155.00%
Syndax Pharmaceuticals
Nov 21, 2024
Maintains: Overweight
Price Target: $33 → $38
Current: $13.08
Upside: +190.52%
Cogent Biosciences
Nov 14, 2024
Maintains: Overweight
Price Target: $19 → $21
Current: $8.03
Upside: +161.52%
Solid Biosciences
Nov 12, 2024
Maintains: Overweight
Price Target: $15 → $12
Current: $3.27
Upside: +266.97%
Amicus Therapeutics
Nov 12, 2024
Maintains: Overweight
Price Target: $16 → $17
Current: $9.41
Upside: +80.66%
RAPT Therapeutics
Nov 11, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.20
Upside: -
Vera Therapeutics
Nov 5, 2024
Maintains: Overweight
Price Target: $72 → $75
Current: $33.37
Upside: +124.75%
Kiniksa Pharmaceuticals International,
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $18.54
Upside: +115.75%
Zai Lab
Oct 21, 2024
Maintains: Overweight
Price Target: $38 → $44
Current: $26.05
Upside: +68.91%
Oct 4, 2024
Maintains: Overweight
Price Target: $100 → $125
Current: $75.84
Upside: +64.82%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $1.66
Upside: -
Sep 24, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $10.14
Upside: +67.65%
Sep 13, 2024
Maintains: Overweight
Price Target: $20 → $23
Current: $18.37
Upside: +25.20%
Sep 13, 2024
Maintains: Overweight
Price Target: $64 → $57
Current: $29.94
Upside: +90.41%
Sep 4, 2024
Maintains: Overweight
Price Target: $64 → $68
Current: $34.63
Upside: +96.36%
Aug 8, 2024
Maintains: Overweight
Price Target: $33 → $31
Current: $5.66
Upside: +447.70%
Aug 8, 2024
Maintains: Overweight
Price Target: $69 → $66
Current: $22.18
Upside: +197.57%
Aug 7, 2024
Maintains: Overweight
Price Target: $46 → $43
Current: $33.79
Upside: +27.26%
Aug 7, 2024
Maintains: Overweight
Price Target: $173 → $181
Current: $143.26
Upside: +26.34%
Aug 6, 2024
Maintains: Neutral
Price Target: $12 → $10
Current: $7.08
Upside: +41.24%
Aug 6, 2024
Maintains: Overweight
Price Target: $38 → $36
Current: $12.54
Upside: +187.08%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.88
Upside: -
May 3, 2024
Maintains: Overweight
Price Target: $177 → $175
Current: $118.00
Upside: +48.31%
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $0.84
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $4.20
Upside: +209.52%
Mar 27, 2024
Maintains: Overweight
Price Target: $19 → $18
Current: $9.58
Upside: +87.89%
Dec 22, 2023
Downgrades: Underweight
Price Target: n/a
Current: $9.28
Upside: -
Aug 16, 2023
Maintains: Neutral
Price Target: $8 → $9
Current: $0.95
Upside: +849.37%
Jul 25, 2023
Downgrades: Underweight
Price Target: n/a
Current: $7.17
Upside: -
Nov 10, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.71
Upside: -
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $6.57
Upside: +3,705.18%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.60
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $45.74
Upside: +26.80%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $8.58
Upside: +39.86%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $10.11
Upside: +265.97%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $36.82
Upside: +49.38%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $1.85
Upside: +1,413.51%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $32.42
Upside: +66.56%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.49
Upside: +9,027.79%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $14.13
Upside: +91.08%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $8.00
Upside: +400.00%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $246.27
Upside: -44.37%
Dec 24, 2019
Initiates: Overweight
Price Target: $39
Current: $6.16
Upside: +533.12%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $7.15
Upside: +571.33%
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $12.45
Upside: -
Mar 6, 2018
Maintains: Overweight
Price Target: $15 → $18
Current: $0.93
Upside: +1,835.69%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $2.54
Upside: +1,081.10%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $43.84
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.66
Upside: -